替吉奥治疗老年晚期胃癌的临床观察  

Clinical study of tegafur treating elderly advanced gastric cancer

作　　者：周琴[1] 朱海鹏[1] 胡军[1] 吴克雄[1] 

机构地区：[1]新疆维吾尔自治区克拉玛依市中心医院血液肿瘤科,834000

出　　处：《中国医药》2013年第12期1726-1727,共2页China Medicine

摘　　要：目的观察口服替吉奥治疗老年晚期胃癌的疗效和不良反应。方法23例老年进展期胃癌患者，口服替吉奥胶囊，40～60mg/次，2次／d，连续服用4周，休息2周，6周为1个周期，2个周期后评价疗效和不良反应。结果23例中完全缓解0例，部分缓解8例（34．7％）、稳定9例（34．7％）、进展6例（26．1％），有效率（完全缓解＋部分缓解）为34．7％，肿瘤控制率（完全缓解＋部分缓解＋稳定）为73．9％。主要不良反应为骨髓抑制，胃肠道反应，色素沉着等。结论替吉奥是治疗进展期胃癌安全、有效的药物，特别适宜于老年体弱的患者。Objective To evaluate the efficacy and toxicity of tegafur for elderly advanced gastric cancer. Methods Twenty-three elderly patients with advanced gastric cancer were treated with tegafur capsule 40-60 mg each time, two times perday. The evaluation of efficacy and toxicity were performed on all patients after 2 cycles. Results Of the 23 patients,there were 0（ 0% ） complete remission（CR） ,8 （34.7%） partial remission（ PR）, 9 （ 34.7 % ） stable disease （SD） and 6 （ 26.1% ） progression disease （PD）. The total response rate （ CR ＋ PR） was 34.7%. The disease control rate （ CR ＋ PR ＋ SD ） was 73.9%. The major toxicities included myelo suppression, gastrointestinal reaction and cutaneous pigmentation. Conclusion Tegafur is safe and effective in the treatment of advanced gastric cancer, especially for old and frail patients.

关 键 词：胃肿瘤 老年 替吉奥 化学治疗 

分 类 号：R735.2[医药卫生—肿瘤]